Eikon Therapeutics to Participate in Cantor KOL PARP-Inhibitor Event
Eikon Therapeutics (EIKN) says it will participate in a KOL event on the therapeutic use of PARP inhibitors in oncology hosted by Cantor Fitzgerald.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.